Dr. Edward Garon On The Future Of Combination Treatments In Lung Cancer

Dr. Edward Garon on the Future of Combination Treatments in Lung Cancer

Targeted Oncology

Dr. Garon on Concerns for Immunotherapy Combinations in Lung Cancer

Dr. Edward Garon—Connecting for Lung Cancer Cures

UCLA Jonsson Comprehensive Cancer Center

Immunotherapy Combinations: Is this the Future for Treating Lung Cancer?

GRACE - Global Resource for Advancing Cancer Education

What is the future of combination therapy for lung cancer?

You and Lung Cancer

Dr. Garon on Incorporating Immunotherapies into Lung Cancer Treatment

Dr. Garon on Future of Immunotherapy in NSCLC

Dr. Garon Discusses Immunotherapy as Salvage Treatment for Advanced Lung Cancer

Dr. Garon on Antiangiogenic Agents in Lung Cancer

Edward B. Garon, MD, considers the implications of Keynote-001 in advanced NSCLC

Dr. Garon on the Expanding Treatment Landscape in Lung Cancer

Dr. Garon on Immunotherapy for Patients With NSCLC

Future Directions and Ongoing Research in Precision Medicine for Lung Cancer

Dr. Garon on Immunotherapy Combinations in NSCLC

Edward Garon, MD, examines the ADAURA clinical study regarding adjuvant treatment in NSCLC

Edward Garon, MD, discusses length of use when combining I-O with chemotherapy in 1st line NSCLC

Edward Garon, MD, examines dual immunotherapy approach in the CITYSCAPE trial

Dr. Garon on Sequencing of Agents for Advanced Lung Cancer

Dr. Garon on Potential for Immunotherapy in EGFR+ NSCLC

Edward Garon MD, expounds on the new FDA approval of erlotinib + ramuciramab in EGFR positive aNSCLC